Nanopublications LDF server

Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RANqKCxcsUZmefrwxh1LoPNeI8bMzneuDgcQvv3ohkbVo#assertion>. }

• association type Statement assertion.
• association label "carefully consider the potential benefits and risks of naprosyn ec naprosyn anaprox anaprox ds or naprosyn suspension and other treatment options before deciding to use naprosyn ec naprosyn anaprox anaprox ds or naprosyn suspension use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warnings naproxen as naprosyn ec naprosyn anaprox anaprox ds or naprosyn suspension is indicated for the relief of the signs and symptoms of rheumatoid arthritis for the relief of the signs and symptoms of osteoarthritis for the relief of the signs and symptoms of ankylosing spondylitis for the relief of the signs and symptoms of juvenile arthritis naproxen as naprosyn suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient s weight naproxen as naprosyn anaprox anaprox ds and naprosyn suspension is also indicated for relief of the signs and symptoms of tendonitis for relief of the signs and symptoms of bursitis for relief of the signs and symptoms of acute gout for the management of pain for the management of primary dysmenorrhea ec naprosyn is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen containing products see clinical pharmacology dosage and administration" assertion.
• association object DOID_2965 assertion.
• association predicate treats assertion.
• association subject drugbank:DB00788 assertion.
• association relation SymptomaticReliefIndication assertion.
• drugbank:DB00788 category Drug assertion.
• DOID_2965 category Disease assertion.
• association provided_by NeuroDKG assertion.
• association association_type ChemicalToDiseaseOrPhenotypicFeatureAssociation assertion.